AU Patent

AU2023283369A1 — Treating cancers with combinations of acylfulvenes with ibrutinib or bortezomib

Assigned to Lantern Pharma Inc · Expires 2025-01-02 · 1y expired

What this patent protects

A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of Bortezomib, Ibrutinib or an analog, derivative…

USPTO Abstract

A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of Bortezomib, Ibrutinib or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein. The cancer may be refractory to Bortezomib and/or Ibrutinib

Drugs covered by this patent

Patent Metadata

Patent number
AU2023283369A1
Jurisdiction
AU
Classification
—
Expires
2025-01-02
Drug substance claim
No
Drug product claim
No
Assignee
Lantern Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.